Prochlorperazine: Difference between revisions
→Migraine: Fixed typo |
imported>AnomieBOT m Substing templates: {{Format ISBN}}. See User:AnomieBOT/docs/TemplateSubster for info. |
||
| Line 62: | Line 62: | ||
<!-- Definition and medical uses --> | <!-- Definition and medical uses --> | ||
'''Prochlorperazine''', formerly<ref>{{cite web |url=https://www.rxlist.com/compazine-side-effects-drug-center.htm |website=RX List |access-date=14 April 2021|title=Side Effects of Compazine (Prochlorperazine), Warnings, Uses }}</ref> sold under the brand name '''Compazine''' among others, is a medication used to treat [[nausea]], [[migraines]], [[schizophrenia]], [[psychosis]] and [[anxiety]].<ref name=AHFS2019/><ref name=BNF76>{{cite book|title=British national formulary: BNF 76|date=2018|publisher=Pharmaceutical Press|isbn= | '''Prochlorperazine''', formerly<ref>{{cite web |url=https://www.rxlist.com/compazine-side-effects-drug-center.htm |website=RX List |access-date=14 April 2021|title=Side Effects of Compazine (Prochlorperazine), Warnings, Uses }}</ref> sold under the brand name '''Compazine''' among others, is a medication used to treat [[nausea]], [[migraines]], [[schizophrenia]], [[psychosis]] and [[anxiety]].<ref name=AHFS2019/><ref name=BNF76>{{cite book|title=British national formulary: BNF 76|date=2018|publisher=Pharmaceutical Press|isbn=978-0-85711-338-2|pages=385–386|edition=76}}</ref><ref name=AHS2016>{{cite journal | vauthors = Orr SL, Friedman BW, Christie S, Minen MT, Bamford C, Kelley NE, Tepper D | title = Management of Adults With Acute Migraine in the Emergency Department: The American Headache Society Evidence Assessment of Parenteral Pharmacotherapies | journal = Headache | volume = 56 | issue = 6 | pages = 911–940 | date = June 2016 | pmid = 27300483 | doi = 10.1111/head.12835 | doi-access = free }}</ref><ref name="pmid30725768">{{cite book | vauthors = Din L, Preuss CV | chapter = Prochlorperazine | date = March 2022 | title = StatPearls [Internet] | location = Treasure Island (FL) | publisher = StatPearls Publishing | pmid = 30725768 | chapter-url = https://www.ncbi.nlm.nih.gov/books/NBK537083/ }}</ref> It is a less preferred medication for anxiety.<ref name=AHFS2019/> It may be taken [[by mouth]], [[rectal administration|rectally]], [[intravenous|injection into a vein]], or [[intramuscular|injection into a muscle]].<ref name=AHFS2019/> | ||
<!-- Side effects and mechanisms --> | <!-- Side effects and mechanisms --> | ||
| Line 72: | Line 72: | ||
== Medical uses == | == Medical uses == | ||
===Vomiting=== | ===Vomiting=== | ||
Prochlorperazine is used to [[antiemetic|prevent vomiting]] caused by [[chemotherapy]], [[radiation therapy]] and [[Postoperative nausea and vomiting|in the pre- and postoperative setting]].<ref name=Lin2016>{{cite journal | vauthors = Lau Moon Lin M, Robinson PD, Flank J, Sung L, Dupuis LL | title = The Safety of Prochlorperazine in Children: A Systematic Review and Meta-Analysis | journal = Drug Safety | volume = 39 | issue = 6 | pages = 509–516 | date = June 2016 | pmid = 26884326 | doi = 10.1007/s40264-016-0398-9 | s2cid = 39349233 }}</ref> A 2015 Cochrane review found no differences in efficacy among drugs commonly used for this purpose in emergency rooms.<ref>{{cite journal | vauthors = Furyk JS, Meek RA, Egerton-Warburton D | title = Drugs for the treatment of nausea and vomiting in adults in the emergency department setting | journal = The Cochrane Database of Systematic Reviews | issue = 9 | | Prochlorperazine is used to [[antiemetic|prevent vomiting]] caused by [[chemotherapy]], [[radiation therapy]] and [[Postoperative nausea and vomiting|in the pre- and postoperative setting]].<ref name=Lin2016>{{cite journal | vauthors = Lau Moon Lin M, Robinson PD, Flank J, Sung L, Dupuis LL | title = The Safety of Prochlorperazine in Children: A Systematic Review and Meta-Analysis | journal = Drug Safety | volume = 39 | issue = 6 | pages = 509–516 | date = June 2016 | pmid = 26884326 | doi = 10.1007/s40264-016-0398-9 | s2cid = 39349233 }}</ref> A 2015 Cochrane review found no differences in efficacy among drugs commonly used for this purpose in emergency rooms.<ref>{{cite journal | vauthors = Furyk JS, Meek RA, Egerton-Warburton D | title = Drugs for the treatment of nausea and vomiting in adults in the emergency department setting | journal = The Cochrane Database of Systematic Reviews | issue = 9 | article-number = CD010106 | date = September 2015 | volume = 2018 | pmid = 26411330 | pmc = 6517141 | doi = 10.1002/14651858.CD010106.pub2 }}</ref> | ||
===Migraine=== | ===Migraine=== | ||
| Line 81: | Line 81: | ||
== Side effects == | == Side effects == | ||
Sedation is very common, and [[Extrapyramidal symptoms|extrapyramidal side effects]] are common and include restlessness, [[dystonic]] reactions, [[pseudoparkinsonism]], and [[akathisia]]; the extrapyramidal symptoms can affect 2% of people at low doses, whereas higher doses may affect as many as 40% of people.<ref name=Brown1998>{{cite book | vauthors = Brown TM, Stoudemire A | title = Psychiatric Side Effects of Prescription and Over-The-Counter Medications | chapter = Antipsychotics | publisher = American Psychiatric Publishing | year = 1998 | | Sedation is very common, and [[Extrapyramidal symptoms|extrapyramidal side effects]] are common and include restlessness, [[dystonic]] reactions, [[pseudoparkinsonism]], and [[akathisia]]; the extrapyramidal symptoms can affect 2% of people at low doses, whereas higher doses may affect as many as 40% of people.<ref name=Brown1998>{{cite book | vauthors = Brown TM, Stoudemire A | title = Psychiatric Side Effects of Prescription and Over-The-Counter Medications | chapter = Antipsychotics | publisher = American Psychiatric Publishing | year = 1998 | page = 1946 | chapter-url = https://books.google.com/books?id=K7kevbILCuQC&pg=PA1946| isbn = 978-0-88048-868-6 }}</ref><ref>{{cite web|url=https://www.drugs.com/sfx/procot-side-effects.html|title=Procot Side Effects in Detail|website=Drugs.com}}</ref> | ||
Prochlorperazine can also cause a life-threatening condition called [[neuroleptic malignant syndrome]] (NMS). Some symptoms of NMS include high fever, stiff muscles, neck muscle spasms, confusion, irregular pulse or blood pressure, fast heart rate (tachycardia), sweating, and abnormal heart rhythms (arrhythmias). Research from the Veterans Administration and the United States [[Food and Drug Administration]] show injection site reactions. Adverse effects are similar in children.<ref name=Lin2016/> | Prochlorperazine can also cause a life-threatening condition called [[neuroleptic malignant syndrome]] (NMS). Some symptoms of NMS include high fever, stiff muscles, neck muscle spasms, confusion, irregular pulse or blood pressure, fast heart rate (tachycardia), sweating, and abnormal heart rhythms (arrhythmias). Research from the Veterans Administration and the United States [[Food and Drug Administration]] show injection site reactions. Adverse effects are similar in children.<ref name=Lin2016/> | ||
| Line 89: | Line 89: | ||
===Discontinuation=== | ===Discontinuation=== | ||
The [[British National Formulary]] recommends a gradual withdrawal when [[discontinuing antipsychotics]] to avoid acute withdrawal syndrome or rapid relapse.<ref name="Group 2009 192">{{cite book |editor1-first=BMJ | editor = Joint Formulary Committee | title = British National Formulary | edition = 57 | date = March 2009 |publisher=Royal Pharmaceutical Society of Great Britain |location=United Kingdom |isbn=978-0-85369-845-6 |page=192 |chapter=4.2.1 |quote=Withdrawal of antipsychotic drugs after long-term therapy should always be gradual and closely monitored to avoid the risk of acute withdrawal syndromes or rapid relapse.}}</ref> Symptoms of withdrawal commonly include nausea, vomiting, and loss of appetite.<ref name=Had2004>{{cite book | vauthors = Haddad P, Haddad PM, Dursun S, Deakin B |title=Adverse Syndromes and Psychiatric Drugs: A Clinical Guide |date=2004 |publisher=OUP Oxford |isbn= | The [[British National Formulary]] recommends a gradual withdrawal when [[discontinuing antipsychotics]] to avoid acute withdrawal syndrome or rapid relapse.<ref name="Group 2009 192">{{cite book |editor1-first=BMJ | editor = Joint Formulary Committee | title = British National Formulary | edition = 57 | date = March 2009 |publisher=Royal Pharmaceutical Society of Great Britain |location=United Kingdom |isbn=978-0-85369-845-6 |page=192 |chapter=4.2.1 |quote=Withdrawal of antipsychotic drugs after long-term therapy should always be gradual and closely monitored to avoid the risk of acute withdrawal syndromes or rapid relapse.}}</ref> Symptoms of withdrawal commonly include nausea, vomiting, and loss of appetite.<ref name=Had2004>{{cite book | vauthors = Haddad P, Haddad PM, Dursun S, Deakin B |title=Adverse Syndromes and Psychiatric Drugs: A Clinical Guide |date=2004 |publisher=OUP Oxford |isbn=978-0-19-852748-0 |pages=207–216 |url=https://books.google.com/books?id=CWR7DwAAQBAJ&pg=PA207 }}</ref> Other symptoms may include restlessness, increased sweating, and trouble sleeping.<ref name=Had2004/> Less commonly there may be a feeling of the world spinning, numbness, or muscle pains.<ref name=Had2004/> Symptoms generally resolve after a short period of time.<ref name=Had2004/> | ||
There is tentative evidence that discontinuation of antipsychotics can result in psychosis.<ref>{{cite journal | vauthors = Moncrieff J | title = Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse | journal = Acta Psychiatrica Scandinavica | volume = 114 | issue = 1 | pages = 3–13 | date = July 2006 | pmid = 16774655 | doi = 10.1111/j.1600-0447.2006.00787.x | s2cid = 6267180 }}</ref> It may also result in reoccurrence of the condition that is being treated.<ref>{{cite book | vauthors = Sacchetti E, Vita A, Siracusano A, Fleischhacker W |title=Adherence to Antipsychotics in Sc |date=2013 |publisher=Springer Science & Business Media |isbn= | There is tentative evidence that discontinuation of antipsychotics can result in psychosis.<ref>{{cite journal | vauthors = Moncrieff J | title = Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse | journal = Acta Psychiatrica Scandinavica | volume = 114 | issue = 1 | pages = 3–13 | date = July 2006 | pmid = 16774655 | doi = 10.1111/j.1600-0447.2006.00787.x | s2cid = 6267180 }}</ref> It may also result in reoccurrence of the condition that is being treated.<ref>{{cite book | vauthors = Sacchetti E, Vita A, Siracusano A, Fleischhacker W |title=Adherence to Antipsychotics in Sc |date=2013 |publisher=Springer Science & Business Media |isbn=978-88-470-2679-7 |page=85 |url=https://books.google.com/books?id=odE-AgAAQBAJ&pg=PA85 }}</ref> Rarely tardive dyskinesia can occur when the medication is stopped.<ref name=Had2004/> | ||
== Pharmacology == | == Pharmacology == | ||
| Line 204: | Line 204: | ||
==Society and culture== | ==Society and culture== | ||
In the United Kingdom, prochlorperazine is available for the treatment of nausea caused by migraine as a [[Buccal administration|tablet dissolved in the mouth]], and in Australia as a tablet swallowed whole. In the UK, it is available via a prescription and as a [[pharmacy medicine]], meaning it does not require a prescription but is only available after talking with a [[pharmacist]].<ref>{{cite web|title=Buccastem M - Summary of Product Characteristics (SPC) - (eMC)|url=https://www.medicines.org.uk/emc/medicine/22797|publisher=UK Electronic Medicines Compendium|access-date=19 September 2017|date=16 February 2016}}</ref><ref>{{cite web|title=Medicines information|url=http://www.nhs.uk/conditions/Medicinesinfo/Pages/Introduction.aspx|publisher=NHS Choices|access-date=19 September 2017|archive-date=22 October 2017|archive-url=https://web.archive.org/web/20171022015130/https://www.nhs.uk/conditions/medicinesinfo/pages/introduction.aspx | In the United Kingdom, prochlorperazine is available for the treatment of nausea caused by migraine as a [[Buccal administration|tablet dissolved in the mouth]], and in Australia as a tablet swallowed whole. In the UK, it is available via a prescription and as a [[pharmacy medicine]], meaning it does not require a prescription but is only available after talking with a [[pharmacist]].<ref>{{cite web|title=Buccastem M - Summary of Product Characteristics (SPC) - (eMC)|url=https://www.medicines.org.uk/emc/medicine/22797|publisher=UK Electronic Medicines Compendium|access-date=19 September 2017|date=16 February 2016}}</ref><ref>{{cite web|title=Medicines information|url=http://www.nhs.uk/conditions/Medicinesinfo/Pages/Introduction.aspx|publisher=NHS Choices|access-date=19 September 2017|archive-date=22 October 2017|archive-url=https://web.archive.org/web/20171022015130/https://www.nhs.uk/conditions/medicinesinfo/pages/introduction.aspx}}</ref> | ||
===Marketing=== | ===Marketing=== | ||
| Line 226: | Line 226: | ||
== External links == | == External links == | ||
* {{cite web | url = https://druginfo.nlm.nih.gov/drugportal/name/prochlorperazine | publisher = U.S. National Library of Medicine | work = Drug Information Portal | title = Prochlorperazine }} | * {{cite web | url = https://druginfo.nlm.nih.gov/drugportal/name/prochlorperazine | archive-url = https://web.archive.org/web/20190628224236/https://druginfo.nlm.nih.gov/drugportal/name/prochlorperazine | archive-date = June 28, 2019 | publisher = U.S. National Library of Medicine | work = Drug Information Portal | title = Prochlorperazine }} | ||
{{Antipsychotics}} | {{Antipsychotics}} | ||
Latest revision as of 15:42, 2 October 2025
Template:Short description Template:Drugbox
Prochlorperazine, formerly[1] sold under the brand name Compazine among others, is a medication used to treat nausea, migraines, schizophrenia, psychosis and anxiety.[2][3][4][5] It is a less preferred medication for anxiety.[2] It may be taken by mouth, rectally, injection into a vein, or injection into a muscle.[2]
Common side effects include sleepiness, blurry vision, low blood pressure, and dizziness.[2] Serious side effects may include movement disorders including tardive dyskinesia and neuroleptic malignant syndrome.[2] Use in pregnancy and breastfeeding is generally not recommended.[6] It is a typical antipsychotic which is believed to work by reducing the action of dopamine in the brain.[2]
Prochlorperazine was approved for medical use in the United States in 1956.[2] It is available as a generic medication.[3] In 2020, it was the 355th most commonly prescribed medication in the United States, with more than 600Script error: No such module "String".thousand prescriptions.[7][8]
Medical uses
Vomiting
Prochlorperazine is used to prevent vomiting caused by chemotherapy, radiation therapy and in the pre- and postoperative setting.[9] A 2015 Cochrane review found no differences in efficacy among drugs commonly used for this purpose in emergency rooms.[10]
Migraine
Prochlorperazine, generally by intravenous, is used to treat migraine.[11][12] Such use is recommended by The American Headache Society.[4] A 2019 systematic review found prochlorperazine was nearly three times more likely than metoclopramide to relieve headache within 60 minutes of administration.[11]
Labyrinthitis
In the UK prochlorperazine maleate has been used for labyrinthitis, which includes nausea and vertigo.[13]
Side effects
Sedation is very common, and extrapyramidal side effects are common and include restlessness, dystonic reactions, pseudoparkinsonism, and akathisia; the extrapyramidal symptoms can affect 2% of people at low doses, whereas higher doses may affect as many as 40% of people.[14][15]
Prochlorperazine can also cause a life-threatening condition called neuroleptic malignant syndrome (NMS). Some symptoms of NMS include high fever, stiff muscles, neck muscle spasms, confusion, irregular pulse or blood pressure, fast heart rate (tachycardia), sweating, and abnormal heart rhythms (arrhythmias). Research from the Veterans Administration and the United States Food and Drug Administration show injection site reactions. Adverse effects are similar in children.[9]
Warning
The FDA-approved label for prochlorperazine includes a warning for increased risk of mortality in elderly patients with dementia-related psychosis.[16]
Discontinuation
The British National Formulary recommends a gradual withdrawal when discontinuing antipsychotics to avoid acute withdrawal syndrome or rapid relapse.[17] Symptoms of withdrawal commonly include nausea, vomiting, and loss of appetite.[18] Other symptoms may include restlessness, increased sweating, and trouble sleeping.[18] Less commonly there may be a feeling of the world spinning, numbness, or muscle pains.[18] Symptoms generally resolve after a short period of time.[18]
There is tentative evidence that discontinuation of antipsychotics can result in psychosis.[19] It may also result in reoccurrence of the condition that is being treated.[20] Rarely tardive dyskinesia can occur when the medication is stopped.[18]
Pharmacology
| Site | Ki (nM) | Species | Ref |
|---|---|---|---|
| 5-HT1A | 5,888 | Human | [21] |
| 5-HT2A | 7.24 | Human | [21] |
| 5-HT2C | 123 | Human | [21] |
| 5-HT3 | 1349 | Human | [21] |
| 5-HT6 | 148 | Human | [21] |
| 5-HT7 | 6,760 | Human | [21] |
| α1 | 24 | Human | [22] |
| α2 | 1700 | Human | [22] |
| M1 | 776 | Human | [21] |
| M2 | 1413 | Human | [21] |
| D1 | 251 | Human | [21] |
| D2 | 2.24 | Human | [21] |
| D3 | 1.82 | Human | [21] |
| D4 | 5.37 | Human | [21] |
| H1 | 6.03 | Human | [23] |
| H3 | 17,378 | Human | [23] |
| H4 | 17783 | Human | [23] |
| DAT | 589 | Human | [21] |
| NET | 600 | Rat | [24] |
Prochlorperazine is thought to exert its antipsychotic effects by blocking dopamine receptors.[25]
Prochlorperazine is analogous to chlorpromazine; both of these agents antagonize dopaminergic D2 receptors in various pathways of the central nervous system. This D2 blockade results in antipsychotic, antiemetic and other effects. Hyperprolactinemia is a side effect of dopamine antagonists as blockade of D2 receptors within the tuberoinfundibular pathway results in increased plasma levels of prolactin due to increased secretion by lactotrophs in the anterior pituitary.
Following intramuscular injection, the antiemetic action is evident within 5 to 10 minutes and lasts for three to four hours. Rapid action is also noted after buccal treatment. With oral dosing, the start of action is delayed but the duration is somewhat longer (approximately six hours).
Society and culture
In the United Kingdom, prochlorperazine is available for the treatment of nausea caused by migraine as a tablet dissolved in the mouth, and in Australia as a tablet swallowed whole. In the UK, it is available via a prescription and as a pharmacy medicine, meaning it does not require a prescription but is only available after talking with a pharmacist.[26][27]
Marketing
Prochlorperazine is available as tablets, suppositories, and in an injectable form.[28]
As of September 2017 it was marketed under the trade names Ametil, Antinaus, Buccastem, Bukatel, Chlormeprazine, Chloropernazine, Compazine, Compro, Daolin, Dhaperazine, Emedrotec, Emetiral, Eminorm, Lotamin, Mitil, Mormal, Nautisol, Novamin, Novomit, Proazine, Procalm, Prochlorperazin, Prochlorperazine, Prochlorpérazine, Prochlorperazinum, Prochlozine, Proclorperazina, Promat, Promin, Promtil, Roumin, Scripto-metic, Seratil, Stemetil, Steremal, Vergon, Vestil, and Volimin.[28][29]
Historical Formulations
Prochlorperazine was combined with paracetamol and marketedScript error: No such module "Unsubst". for humans as the combination drug Vestil-A; it was combined with isopropamide (brand name Darbazine) as a combination drug for veterinary use.[28]
Until 1981, a combination diet pill composed of prochlorperazine and dextroamphetamine was marketed as Eskatrol in the United States by Smith, Kline & French Laboratories.
Research
Alexza Pharmaceuticals studied an inhaled form of prochlorperazine for the treatment of migraine through Phase II trials under the development name AT-001; development was discontinued in 2011.[30]
Synthesis
The alkylation of 2-chlorophenothiazine (1) and 1-(3-Chloropropyl)-4-methylpiperazine [104-16-5] (2) in the presence of sodamide gives Prochlorperazine (3); or by alkylation of 2-Chloro-10-(3-chloropropyl)phenothiazine [2765-59-5] (4) and 1-methylpiperazine (5).
References
<templatestyles src="Reflist/styles.css" />
- ↑ Script error: No such module "citation/CS1".
- ↑ a b c d e f g Script error: No such module "citation/CS1".
- ↑ a b Script error: No such module "citation/CS1".
- ↑ a b Script error: No such module "Citation/CS1".
- ↑ Script error: No such module "citation/CS1".
- ↑ Script error: No such module "citation/CS1".
- ↑ Script error: No such module "citation/CS1".
- ↑ Script error: No such module "citation/CS1".
- ↑ a b Script error: No such module "Citation/CS1".
- ↑ Script error: No such module "Citation/CS1".
- ↑ a b Script error: No such module "Citation/CS1".
- ↑ Script error: No such module "Citation/CS1".
- ↑ Script error: No such module "Citation/CS1".
- ↑ Script error: No such module "citation/CS1".
- ↑ Script error: No such module "citation/CS1".
- ↑ Script error: No such module "citation/CS1".
- ↑ Script error: No such module "citation/CS1".
- ↑ a b c d e Script error: No such module "citation/CS1".
- ↑ Script error: No such module "Citation/CS1".
- ↑ Script error: No such module "citation/CS1".
- ↑ a b c d e f g h i j k l m Script error: No such module "Citation/CS1".
- ↑ a b Script error: No such module "Citation/CS1".
- ↑ a b c Script error: No such module "Citation/CS1".
- ↑ Script error: No such module "Citation/CS1".
- ↑ Script error: No such module "citation/CS1".
- ↑ Script error: No such module "citation/CS1".
- ↑ Script error: No such module "citation/CS1".
- ↑ a b c Script error: No such module "citation/CS1".
- ↑ Script error: No such module "citation/CS1".
- ↑ Script error: No such module "Citation/CS1".
- ↑ J. Gen. Chem. USSR (Engl. Transl.), vol. 32, p. 1915 - 1919,1892 – 1895.
- ↑ GB780193 idem Horclois Raymond Jacques, U.S. patent 2902484 (1959 to Rhone Poulenc Sa).
Script error: No such module "Check for unknown parameters".
External links
- Script error: No such module "citation/CS1".
Script error: No such module "Navbox".
Script error: No such module "navboxes". Template:Adrenergic receptor modulators Template:Dopamine receptor modulators Template:GHB receptor modulators Template:Histamine receptor modulators Template:Serotonin receptor modulatorsScript error: No such module "navboxes".Script error: No such module "Check for unknown parameters". Template:Tricyclics Template:Portal bar